&nbsp;

Jul 2025

Regimen

AZCTIVOS

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

New Drug Funding Program

Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Drugs Used:

ivosidenib,

azaCITIDine

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Nov 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

Exceptional Access Program

alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Nov 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Regimen

ASCI

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria

Drugs Used:

asciminib

Quick Link(s):

Regimen Monograph

Drug

acalabrutinib

Other Name(s): Calquence®

Quick Link(s):

Dec 1969

Drug

abemaciclib

Other Name(s): Verzenio®

Quick Link(s):

Oct 2025

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Regimen

ACALBEND+RITU; ACAL+RITU(MNT)

Cancer Type:

Hematologic

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Exceptional Access Program

acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used: